Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc (VOR) is a clinical-stage biotechnology pioneer developing engineered hematopoietic stem cell (eHSC) therapies for hematological cancers. This page serves as the definitive source for verified corporate announcements, clinical trial updates, and strategic developments related to their innovative platform.
Investors and researchers will find timely updates on key milestones including trial progress, regulatory filings, and partnership announcements. All content is curated to provide actionable insights into the company’s novel approach to protecting healthy cells during cancer treatments while enabling targeted tumor eradication.
The resource features press releases covering financial results, manufacturing advancements, and peer-reviewed research publications. Scientific updates detail progress in their eHSC platform’s applications for CAR-T therapies and antigen-targeted treatment regimens.
Bookmark this page for streamlined access to Vor Biopharma’s latest developments in cell engineering and hematological oncology research. Regularly updated to reflect new data presentations, clinical collaborations, and pipeline expansions.
Vor Biopharma (Nasdaq: VOR) will participate in B. Riley Securities’ 3rd Annual Oncology Conference, held virtually on January 18, 2023, at 12:00 PM ET. The event aims to showcase advancements in oncology and will include a fireside chat format. A live webcast of the presentation will be accessible on the company's website, with an archived replay available afterward. Vor Biopharma focuses on transforming the standard of care for blood cancer patients through innovative genome engineering of hematopoietic stem cells.
Vor Bio (Nasdaq: VOR) has announced a dual fundraising initiative, pricing an underwritten offering and a private placement, aiming for combined gross proceeds of approximately $115.8 million. The underwritten offering includes 15,302,267 shares at $4.30 per share, expected to yield about $65.8 million, set to close around December 9, 2022. Concurrently, 11,627,907 shares will be sold privately to RA Capital for an additional $50 million. Proceeds will target clinical development and general corporate needs.
Vor Bio has announced promising initial clinical data from its Phase 1/2a trial of trem-cel (formerly VOR33) for acute myeloid leukemia (AML). The first patient's results indicate successful engraftment and maintenance of blood counts after treatment with Mylotarg. A total of 7.6 x106 CD34+ cells/kg were infused, achieving 100% donor chimerism and robust hematopoietic reconstitution. No adverse events related to Mylotarg were noted, highlighting the treatment's tolerability. A conference call discussing these developments is scheduled for December 7, 2022.
Vor Bio (Nasdaq: VOR), a clinical-stage company focusing on cell and genome engineering, will participate in several investor conferences. The Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, at 9:30 am ET in New York. A fireside chat at the 5th Annual Evercore ISI HealthCONx Virtual Conference will occur on December 1 at 3:05 pm ET, followed by another fireside chat at The JMP Securities Hematology and Oncology Virtual Summit on December 6 at 1:20 pm ET. Webcasts of these events will be available on their website.
Vor Bio reported financial results for Q3 2022, showing a cash position of $136.1 million, projected to fund operations until Q1 2024. R&D expenses increased to $16.9 million, driven by clinical trials and facility expansions. The net loss was $23.8 million. In-house clinical manufacturing is now operational, supporting the IND submission for VCAR33 in H1 2023. The company plans to present initial clinical data for VOR33 by the end of 2022 and has received ATMP status from EMA for VOR33 and VCAR33.
Vor Bio (Nasdaq: VOR) has announced its participation in several upcoming investor conferences. Key events include:
- Credit Suisse 31st Annual Healthcare Conference: Virtual presentation on November 8, 2022.
- Stifel 2022 Healthcare Conference: Fireside chat on November 16, 2022, at 10:20 am EST in New York, NY.
- Jefferies London Healthcare Conference: Fireside chat on November 17, 2022, at 3:15 pm GMT in London, UK.
Webcasts of these events will be available on Vor Bio's investor section.
Vor Bio (Nasdaq: VOR) has appointed Dr. Eyal C. Attar as Chief Medical Officer, bringing over 20 years of clinical experience, particularly in hematologic malignancies. The company anticipates important clinical trial data for VOR33 later this year, alongside an IND submission for VCAR33ALLO planned for early next year. Dr. Attar's expertise in AML and prior roles at Aprea Therapeutics and Agios Pharmaceuticals are expected to enhance Vor Bio's clinical development capabilities. An inducement equity award of 364,000 stock options was granted to Dr. Attar as part of his appointment.
Vor Bio (Nasdaq: VOR) presented promising preclinical data on its novel base editing platform for hematopoietic stem cell (HSC) engineering at the ESGCT Annual Congress in Edinburgh. Their research showcased the successful multiplex deletion of myeloid antigens CD33 and CLL-1, which maintained HSC function and exhibited long-term engraftment without genotoxic risks. This innovative approach is aimed at improving safety and efficacy for treating acute myeloid leukemia (AML), addressing significant challenges in current therapies.
Vor Bio has opened a new in-house clinical manufacturing facility in Cambridge, MA, to enhance the production of engineered hematopoietic stem cells (eHSCs) and CAR-T therapies targeting blood cancers. This facility aims to improve integration across teams, reduce manufacturing time and cost, and boost operational efficiency for ongoing clinical trials. The facility includes four cleanrooms and is designed to comply with Good Manufacturing Practice (cGMP) standards. The company plans to support the IND submission for VCAR33 by mid-2023.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced its participation in several investor conferences in September 2022.
The events include:
- Morgan Stanley 20th Annual Global Healthcare Conference: September 12, 2022, at 4:50 pm ET in New York, NY
- H.C. Wainwright 24th Annual Global Investment Conference: September 14, 2022, at 8:30 am ET in New York, NY
- Baird’s 2022 Global Healthcare Conference: September 14, 2022, at 10:50 am ET in New York, NY
- Jefferies Cell and Genetic Medicine Summit: September 30, 2022, in New York, NY
A live webcast of the Morgan Stanley chat will be available on vorbio.com.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
